SecBot SecBot
8-K ·Filed Nov 5, 2026

RIGL

RIGEL PHARMACEUTICALS INC
BEARISH
Impact 5/10
Horizondays Processed11d 10h ago SEC0001034842-26-000062
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The EPS miss and rising expense base (R&D + SG&A up 55% YoY) overshadow the VEPPANU launch. Monitor the Q4 2026 VEPPANU sales trajectory and the R289 Phase 2 dose selection by year-end for the next catalyst.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$39.65
T+0 close · Nov 5, 2026 · via day close
Latest settled
+12.13%
T+5 · $44.46 · next T+20 in 20d
Vs SPY
+9.54%
α at T+5
Latest observation
+11.36%
T+6 · FF3 residual α
  1. T+0 · Nov 6 $39.65entry
  2. T+1 · 8d ago +6.05%α +3.69% · $42.05
  3. T+5 · 4d ago +12.13%α +9.54% · $44.46
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Rigel Pharmaceuticals reported Q3 2026 revenue of $80.9M (above $80.1M consensus) and GAAP EPS of $0.65 diluted (below $0.96 consensus, a miss). Net product sales grew 13% YoY to $72.3M, driven by the VEPPANU launch ($6.6M in initial sales), but net income fell to $13.2M from $27.9M a year ago due to higher R&D and commercial costs. The company narrowed its 2026 total revenue guidance to $290-$295M (excluding VEPPANU), up slightly from the prior $285-$295M range.

Key Financial Metrics

EPS
$0.65
est $0.96 · -32.3%
Revenue
$80.9M
est $80.1M · +1.0% · +16.4% YoY
Rating
miss
Guidance
$290M-$295M
raised

Key Facts

  • Q3 2026 total revenues of $80.9M, net product sales of $72.3M (+13% YoY), contract revenues of $8.6M
  • GAAP net income of $13.2M ($0.65 diluted EPS) vs $27.9M ($1.46 diluted) in Q3 2025
  • VEPPANU (vepdegestrant) launched mid-August, generated $6.6M in initial net product sales
  • EPS of $0.65 diluted missed consensus estimate of $0.96
  • Revenue of $80.9M slightly above consensus of $80.1M
  • 2026 total revenue guidance updated to ~$290-$295M (ex-VEPPANU), from prior ~$285-$295M
  • Cash and short-term investments fell to $99.3M from $155.0M at year-end 2025
  • R&D expense more than doubled to $18.3M from $7.4M in Q3 2025, driven by R289 and vepdegestrant programs

Financial Impact

GAAP diluted EPS of $0.65 vs consensus $0.96 (32% miss); revenue $80.9M vs $80.1M consensus (1% beat). Net income declined 53% YoY.

epsnet incomeoperating expensescash balance

Segment Breakdown

SegmentRevenueGrowth
TAVALISSE net product sales$46.0M+3.0%
REZLIDHIA net product sales$9.9M+20.0%
GAVRETO net product sales$9.8M-11.0%
VEPPANU net product sales$6.6MNot reported

Risk Factors

  • EPS miss of 32% vs consensus may pressure the stock near-term
  • Cash burn accelerated: cash dropped $55.7M from Dec 2025 to Sep 2026
  • VEPPANU launch is early; sustainability of $6.6M quarterly run-rate is unproven
  • R&D spending likely to remain elevated with two late-stage programs

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
73% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001034842-26-000062
Document: 0001034842-26-000062-index.html0001034842-26-000062
Document: 0001034842-26-000062.txt0001034842-26-000062
8-K Data (Synthetic)0001034842-26-000062

Track record

12 reports on RIGL

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +25.02% at T+60 after the May 12, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $45.03 Now $43.73 −2.89% settles Feb 12
  2. Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $44.21 Now $43.73 −1.09% settles Feb 12
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $43.91 Now $43.73 −0.41% settles Feb 8
  4. Nov 5, 202611d ago 8-K Bearish 5/10 Viewing Entry $39.65 Now $43.73 −10.29% settles Feb 4
  5. Aug 4, 202614w ago 8-K Mixed 6/10 Entry $40.48 to $50.92 Now $43.73 +8.03% ▲ +25.79% +25.60% vs SPY
  6. Jun 17, 202621w ago 8-K Neutral 4/10 Entry $32.91 to $45.35 Now $43.73 +32.88% ▲ +37.80% +35.91% vs SPY
  7. Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $32.08 to $48.67 Now $43.73 +36.32% ▲ +51.71% +47.32% vs SPY
  8. May 20, 202625w ago 8-K Neutral 2/10 Entry $29.19 to $42.45 Now $43.73 +49.81% ▲ +45.43% +41.13% vs SPY
  9. May 12, 202626w ago 8-K Bullish 7/10 Entry $32.13 to $40.17 Now $43.73 +36.10% ▲ +25.02% +20.59% vs SPY
  10. May 5, 202627w ago 8-K Bearish 7/10 Entry $26.67 to $36.81 Now $43.73 −63.97% ▼ −38.02% −35.96% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026